ATP生物荧光肿瘤体外药物敏感性检测在乳腺癌中的应用

The Application of ATP Bioluminescence In Vitro Tumor Chemosensitivity Assay in Breast Cancer

目的 评价ATP生物荧光肿瘤体外药物敏感性检测结果是否能真实反映肿瘤的药敏情况以及该方法指导制定化疗方案的可行性。方法 应用ATP生物荧光肿瘤体外药物敏感性检测法 ,检测 4 2例乳腺癌标本对 12种常用药物的敏感性。结果 标本的可评价率为 95 % ,乳腺癌对PTX最敏感 ,体外有效率为 93% ,其次为ADM(6 7% )和 5 Fu(6 4 % ) ,体外有效病例中强敏感病例比例最高的为PTX ,达到6 9 % ,其次为ADM(6 1% )和 5 Fu(5 6 % ) ,检测结果与临床疗效相符。ER/PR、PCNA、p5 3、c erbB 2、绝经与否、淋巴结转移与否与药物是否有效无关。结论 ATP生物荧光肿瘤体外药物敏感性检测法敏感性高、稳定性好、简便、快速 ,检测结果真实可信 ,可用于临床制定个体化的化疗方案。

Objective To study whether ATP bioluminescence in vitro tumor chemosensitivity assay(ATP-TCA) can reflect the status of tumor chemosensitivity as they really are and the feasibility of designing chemotherapy based on ATP-TCA. Methods We tested the specimens from 42 breast cancer patients for chemosensitivity of 12 anticancer drugs using ATP-TCA. Results Available evaluation of specimen is 95%, PTX is the most sensitive drug to breast cancer and its in vitro effective rate is 93%, followed by ADM(67%) and 5-Fu(64%). On account of the strong sensitive cases in all in vitro effective cases, PTX has the biggest proportion which is 69%, followed by ADM(61%) and 5-Fu(56%). The assay results corresponded with clinical response. ER/PR, PCNA, p53, c-erbB-2, menopause status, lymph node metastasis status are not related to drug effective (P> 0.05). Conclusion ATP-TCA is an easy and rapid assay with high sensitivity as well as good stability. Its result is true and can be believed in, which can be used to design personal chemotherapy in clinical practice.